{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:05:07Z","timestamp":1780463107007,"version":"3.54.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:00:00Z","timestamp":1663891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>It is necessary to select suitable inactivated poliovirus vaccine(IPV) and live, attenuated oral poliovirus vaccine (OPV) sequential immunization programs and configure the corresponding health resources. An economic evaluation was conducted on the sequential procedures of Sabin strain-based IPV (sIPV) and bivalent OPV (bOPV) with different doses to verify whether a cost-effectiveness target can be achieved. This study aimed to evaluate the cost-effectiveness of different sIPV immunization schedules, which would provide convincing evidence to further change the poliovirus vaccine (PV) immunization strategies in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Five strategies were included in this analysis. Based on Strategy 0(S<jats:sub>0<\/jats:sub>), the incremental cost (IC), incremental effect (IE), and incremental cost-effectiveness ratio (ICER) of the four different strategies (S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub>) were calculated based on the perspective of the society. Seven cost items were included in this study. Results of field investigations and expert consultations were used to calculate these costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The ICs of S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub> was Chinese Yuan (CNY) 30.77, 68.58, 103.82, and 219.82 million, respectively. The IE of vaccine-associated paralytic poliomyelitis (IE<jats:sub>VAPP<\/jats:sub>) cases of S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub> were 0.22, 0.22, 0.22, and 0.11, respectively, while the IE of disability-adjusted life-years (IE<jats:sub>DALY<\/jats:sub>) of S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub> were 8.98, 8.98, 8.98, and 4.49, respectively. The ICER<jats:sub>VAPP<\/jats:sub> of S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub> gradually increased to CNY 13.99, 31.17, 47.19, and 199.83 million\/VAPP, respectively. The ICER<jats:sub>DALY<\/jats:sub> of S<jats:sub>1<\/jats:sub>\/S<jats:sub>2<\/jats:sub>\/S<jats:sub>3<\/jats:sub>\/S<jats:sub>4<\/jats:sub> also gradually increased to CNY 0.34, 0.76, 1.16, and 4.90 million\/DALY, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ICER<jats:sub>VAPP<\/jats:sub> and ICER<jats:sub>DALY<\/jats:sub> were substantially higher for S<jats:sub>3<\/jats:sub> (four-sIPV) and S<jats:sub>4<\/jats:sub> (replacement of self-funded sIPV based on one-sIPV-three-bOPV). Two-sIPV-two-bOPV had a cost-effectiveness advantage, whereas S2\/S3\/S4 had no cost-effectiveness advantage.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.990042","type":"journal-article","created":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:45:02Z","timestamp":1663933502000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China"],"prefix":"10.3389","volume":"10","author":[{"given":"Yuyang","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinren","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3969\/j.issn.1005-5673.2011.02.017","article-title":"Progress of poliomyelitis vaccine research","volume":"39","author":"Liu","year":"2011","journal-title":"Prog Microbiol Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol."},{"key":"B3","unstructured":""},{"key":"B4","volume-title":"Vaccine. 5th edition","author":"Stanley","year":"2008"},{"key":"B5","first-page":"145","article-title":"Polio vaccines: WHO position paper, March 2016","volume":"91","year":"2016","journal-title":"WER"},{"key":"B6","first-page":"219","article-title":"Global eradication of poliomyelitis by the year 2000","volume":"14","year":"1988","journal-title":"WER"},{"key":"B7","first-page":"49","article-title":"Expanded program on immunization. Poliomyelitis in 1987, 1988 and 1989-Part","volume":"66","year":"1991","journal-title":"WER"},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.vaccine.2011.10.005","article-title":"The global polio eradication initiative lessons learned and prospects for success","volume":"29","author":"Aylward","year":"2011","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1086\/506359","article-title":"An outbreak of poliomyelitis caused by typeIvaccine-derived poliovirus in China","volume":"194","author":"Liang","year":"2006","journal-title":"J Infect Dis."},{"key":"B10","unstructured":"2014"},{"key":"B11","first-page":"18","article-title":"The world's first inactivated vaccine for the Sabin strain of poliomyelitis was approved for marketing","volume":"15","author":"Lane","year":"2015","journal-title":"Eval Anal Drug"},{"key":"B12","first-page":"265","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2016\u2013 conclusions and recommendations","volume":"91","year":"2016","journal-title":"WER"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2017.1288769","article-title":"Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial","volume":"13","author":"Qiu","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B15","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1997"},{"key":"B16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3969\/j.issn.1674-2982.2012.02.012","article-title":"The application of incremental cost-effectiveness ratio to health technology assessment","volume":"5","author":"Zhang","year":"2012","journal-title":"Chin J Health Policy."},{"key":"B17","first-page":"9","article-title":"Cost analysis of post-polio certification immunization policies","volume":"82","author":"Sangrujee","year":"2004","journal-title":"Bull World Health Organ."},{"key":"B18","first-page":"454","article-title":"Evaluation method of cold chain volume based on vaccine volume and inoculation number","volume":"20","author":"Tao","year":"2014","journal-title":"Chin J Vaccine Immun."},{"key":"B19","unstructured":"User Guide for WHO Vaccine Volume Calculator [EB\/OL]. WHO"},{"key":"B20","article-title":"The world health organization (WHO) about the use of oral polio vaccine introduced inactivated polio inactivated opinion","volume":"78","year":"2003","journal-title":"Epidemiol Wkly"},{"key":"B21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/infdis\/jiu184","article-title":"Vaccine-Associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden","volume":"210","author":"Platt","year":"2014","journal-title":"J Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.vaccine.2017.01.034","article-title":"Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014","volume":"35","author":"Liu","year":"2017","journal-title":"Vaccine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1016\/j.vaccine.2006.05.032","article-title":"The cost-effectiveness of alternative polio immunizationpolicies in South Africa","volume":"24","author":"Ulla","year":"2006","journal-title":"Vaccine."},{"key":"B24","volume-title":"Strategic Analysis and Cost Estimation of Using SABin-IPV Instead of OPV in The Late Stage of Poliomyelitis Eradication in China","author":"Li","year":"2007"},{"key":"B25","first-page":"169","article-title":"Economic burden of poliomyelitis","volume":"17","author":"Dai","year":"1996","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi."},{"key":"B26","volume-title":"In the Field of Medical and Health Care Cost\u2014Benefit Analysis","author":"Cheng","year":"1994"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.15585\/mmwr.mm7049a1","article-title":"Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021","volume":"70","author":"Alleman","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"ofab535","DOI":"10.1093\/ofid\/ofab535","article-title":"Circulation of type 2 vaccine-derived poliovirus in China in 2018-2019","volume":"8","author":"Zhao","year":"2021","journal-title":"Open Forum Infect Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.bsheal.2019.12.002","article-title":"Type I vaccine-derived polioviruses in China from 1995 to 2019","volume":"3","author":"Zhang","year":"2019","journal-title":"Biosaf Health."},{"key":"B30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/erv.11.195","article-title":"Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation","volume":"11","author":"Thompson","year":"2012","journal-title":"Expert Rev Vaccines."},{"key":"B31","first-page":"210","article-title":"Epidemiological characteristics of vaccine-derived poliovirus and its cases in China from 2001 to 2013","volume":"20","author":"Wen","year":"2014","journal-title":"Chin J Vaccine Immun."},{"key":"B32","unstructured":"WHO Guide to Generalized Cost-Effectiveness Analysis [EB\/OL]. WHO"},{"key":"B33","volume-title":"Incremental Cost Study of Inactivated Poliovirus Vaccine into National Immunization Program.","author":"Yang","year":"2015"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1590\/S0034-8910.2015049005492","article-title":"Polio inactivated vaccine costs into routine childhood immunization in Brazil","volume":"49","author":"Sartori","year":"2015","journal-title":"Rev Saude Publica."},{"key":"B35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.puhe.2016.10.016","article-title":"Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization","volume":"142","author":"Khan","year":"2017","journal-title":"Public Health."},{"key":"B36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/infdis\/jit588","article-title":"Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's national immunization program","volume":"210","author":"Domingues","year":"2014","journal-title":"J Infect Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12879-015-1112-8","article-title":"An economic analysis of poliovirus risk management policy options for 2013-2052","volume":"15","author":"Duintjer Tebbens","year":"2015","journal-title":"BMC Infect Dis."},{"key":"B38","unstructured":"2013"},{"key":"B39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1586\/14760584.2014.864563","article-title":"National choices related to inactivated poliovirus vaccine, innovation, and the end game of global polio eradication","volume":"13","author":"Thompson","year":"2014","journal-title":"Exp Rev Vaccines."},{"key":"B40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","article-title":"Economic analysis of the global polio eradication initiative","volume":"29","author":"Tebbens","year":"2010","journal-title":"Vaccine."},{"key":"B41","volume-title":"Principles and Considerations for Adding a Vaccine to a National Immunization Programme: From Decision to Implementation and Monitoring","year":"2014"},{"key":"B42","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1590\/S1020-49892010000500005","article-title":"Economic impact of introducing the injectable inactivated polio vaccine in Colombia","volume":"27","author":"Alvis","year":"2010","journal-title":"Rev Panam Salud Publica."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.3390\/vaccines9101062","article-title":"Cost-Effectiveness of three poliovirus immunization schedules in Shanghai, China","volume":"9","author":"Ren","year":"2021","journal-title":"Vaccines."},{"key":"B44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijid.2018.08.017","article-title":"Vaccine-associated paralytic poliomyelitis in the Russian federation in 1998\u20132014","volume":"76","author":"Ivanova","year":"2018","journal-title":"Int J Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.292.14.1696","article-title":"Vaccine policy changes and epidemiology of poliomyelitis in the United States","volume":"292","author":"Alexander","year":"2004","journal-title":"JAMA."},{"key":"B46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.276.12.967","article-title":"Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule","volume":"276","author":"Miller","year":"1996","journal-title":"JAMA."},{"key":"B47","unstructured":""},{"key":"B48","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1467-842X.2001.tb00648.x","article-title":"Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia","volume":"25","author":"Tucker","year":"2001","journal-title":"Aust N Z J Public Health."},{"key":"B49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1539-6924.2012.01864.x","article-title":"Expert review on poliovirus immunity and transmission","volume":"33","author":"Duintjer","year":"2013","journal-title":"Risk Anal."},{"key":"B50","doi-asserted-by":"publisher","first-page":"20586","DOI":"10.2807\/1560-7917.ES2013.18.38.20586","article-title":"Insidious reintroduction of wild poliovirus into Israel, 2013","volume":"18","author":"Anis","year":"2013","journal-title":"Euro Surveill."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/infdis\/jiu674","article-title":"Modeling options to manage type 1 wild poliovirus imported into Israel in 2013","volume":"211","author":"Kalkowska","year":"2015","journal-title":"J Infect Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiu060","article-title":"Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmentalsurveillance","volume":"210","author":"Wahjuhono","year":"2014","journal-title":"J Infect Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2105\/AJPH.2007.122192","article-title":"The risks, costs, and benefits of possible future global policies for managing polioviruses","volume":"98","author":"Thompson","year":"2008","journal-title":"Am J Public Health."},{"key":"B54","first-page":"337","article-title":"Analysis of poliomyelitis eradication and recommendations for immunization strategies","volume":"15","author":"Huang","year":"2020","journal-title":"J Microbes Infect."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.vaccine.2016.11.017","article-title":"Polio vaccines: WHO position paper, March 2016\u2014recommendations","volume":"35","year":"2017","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/21645515.2015.1088617","article-title":"Polio elimination in Nigeria: a review","volume":"12","author":"Nasir","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/S0140-6736(07)60532-7","article-title":"Eradication versus control for poliomyelitis: an economic analysis","volume":"369","author":"Thompson","year":"2007","journal-title":"Lancet."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.990042\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T11:45:29Z","timestamp":1663933529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.990042\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,23]]},"references-count":57,"alternative-id":["10.3389\/fpubh.2022.990042"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.990042","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,23]]},"article-number":"990042"}}